Veterinary evidence hub / Oxyglobin & HBOCs

Oxygen therapeutics.
Evidence in context.

Explore the literature by species, follow author institutions and original sources, and distinguish Oxyglobin’s veterinary regulatory history from wider HBOC research.

Explore publications →By species ↓By institution →By author →By journal →
236Total publicationsBibliographic records 10Species / model groupsAnimal, human & in vitro 109Journal labelsNames as recorded; see note 154Author institutionsBrowse the institution directory 235Source-linked citations225 PubMed · 217 DOI links
Browse the bibliography

Species Distribution

236 total records

Select a species or model group to open matching publications.

Canine (Dog)25 Feline (Cat)6 Equine (Horse)4 Porcine (Pig)38 Ovine (Sheep)4 Rodent39 Avian (Birds)18 Exotic / other animals15 Human89 Other / In vitro21

Human and in-vitro records provide wider research context; they are not veterinary approvals. Bar lengths compare group counts, not percentages of a whole.

How to interpret these numbers

Counts are records carrying indexed species or model labels, not counts of confirmed treatment studies. A record can appear in several groups; group counts must not be added to obtain the total. Labels may be incomplete.

Exotic / other animals combines ferret, rabbit and other-animal labels, counting each record once. It does not imply wildlife use. Other / In vitro includes in-vitro labels and 13 records with no species label.

Journal names are normalized for the publication filter: known abbreviations and full-name variants are merged, while non-journal or unclassified source labels appear under Other.

Source bibliography · Index methodology

Inside the original FDA record

A clinical milestone.
A defined endpoint.

The randomised canine field trial reported treatment success in 22 of 30 Oxyglobin-treated dogs versus 10 of 34 controls in the intent-to-treat population.

Read the FDA study summary, pp. 4–8 ↗
Dogs enrolled
64
Oxyglobin / control
73% / 29%
Endpoint window
24 hours

Success meant no additional oxygen-carrying support for 24 hours; it was not a survival endpoint. The FDA report also documents adverse reactions, including pulmonary oedema. Results apply to this trial and product, not to every species or a future formulation.

02 / Scope

Read each finding in context.

Use Library scope to separate BHOC / Oxyglobin-focused records from background literature. Every record remains accessible under All records.

Open scope filter →Understand the index →
03 / Development

Precision oxygen therapeutics.

Explore the proposed BHOC veterinary framework: supporting the oxygen-delivery function of blood while recognising its other essential functions.

Read the concept →

Author affiliations are not institutional endorsements and do not identify treatment locations. Historical Oxyglobin approvals do not establish approval of a new BHOC formulation or human use. Section guide · Full citation catalogue.